← Back to Search
Impact Of Tumor-specific Targeting On The Biodistribution And Efficacy Of SiRNA Nanoparticles Measured By Multimodality In Vivo Imaging
D. Bartlett, H. Su, I. Hildebrandt, W. Weber, M. Davis
Published 2007 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Targeted delivery represents a promising approach for the development of safer and more effective therapeutics for oncology applications. Although macromolecules accumulate nonspecifically in tumors through the enhanced permeability and retention (EPR) effect, previous studies using nanoparticles to deliver chemotherapeutics or siRNA demonstrated that attachment of cell-specific targeting ligands to the surface of nanoparticles leads to enhanced potency relative to nontargeted formulations. Here, we use positron emission tomography (PET) and bioluminescent imaging to quantify the in vivo biodistribution and function of nanoparticles formed with cyclodextrin-containing polycations and siRNA. Conjugation of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid to the 5′ end of the siRNA molecules allows labeling with 64Cu for PET imaging. Bioluminescent imaging of mice bearing luciferase-expressing Neuro2A s.c. tumors before and after PET imaging enables correlation of functional efficacy with biodistribution data. Although both nontargeted and transferrin-targeted siRNA nanoparticles exhibit similar biodistribution and tumor localization by PET, transferrin-targeted siRNA nanoparticles reduce tumor luciferase activity by ≈50% relative to nontargeted siRNA nanoparticles 1 d after injection. Compartmental modeling is used to show that the primary advantage of targeted nanoparticles is associated with processes involved in cellular uptake in tumor cells rather than overall tumor localization. Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics.
This paper references
Bioconjugate Chem 18:456–468
DW Bartlett (2007)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing
D. Bartlett (2007)
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
A. Loening (2003)
Db Kirpotin (2006)
Dw Bartlett (2007)
[General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics].
Y. Matsumura (1987)
Phys Med Biol
Pl Chow (2006)
Ac Riches (1973)
Z Medarova (2007)
In vivo imaging of siRNA delivery and silencing in tumors
Z. Medarova (2007)
Pt Yazdi (1995)
Int J Pharm
Hk De Wolf (2007)
Blood volume determination in the mouse
A. C. Riches (1973)
Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution.
N. Liu (2007)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J. Soutschek (2004)
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
D. Bartlett (2007)
R. Rosenfeld (2009)
A method of image registration for small animal, multi-modality imaging.
P. Chow (2006)
Bioorgan Med Chem
Da Braasch (2004)
Drug Metab Dispos 34:1393–1397
FM van de Water (2006)
Cancer Biol Ther
Sh Pun (2004)
Am J Roentgenol
Bs Kuszyk (2001)
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
G. Adams (1998)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Erwei Song (2005)
Proc Natl Acad Sci
Am Wu (2000)
Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration.
Holger K. de Wolf (2007)
Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.
N. Maeda (2006)
Biodistribution of phosphodiester and phosphorothioate siRNA.
D. A. Braasch (2004)
M Ogris (1999)
Gp Adams (1998)
Release of copper by rat liver.
C. A. Owen (1970)
Tumor transport physiology: implications for imaging and imaging-guided therapy.
B. Kuszyk (2001)
Gene Ther 8:28–40
R Kircheis (2001)
R Kircheis (2001)
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
RNAi-mediated gene silencing in non-human primates
T. Zimmermann (2006)
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
D. Bartlett (2006)
Gene Ther 6:595–605
M Ogris (1999)
Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity
R. Kircheis (2002)
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
S. Hu-Lieskovan (2005)
Clin Cancer Res
Jw Park (2002)
E Song (2005)
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
A. Wu (2000)
INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES
F. M. van de Water (2006)
Biol Pharm Bull
N Maeda (2006)
Nucleic Acids Res Biotechnol Bioeng Loening AM, Gambhir SS Mol Imaging Am J Physiol Drug Metab Dispos
Dw Bartlett (1970)
PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery
M. Ogris (1999)
Cancer Gene Ther
R Kircheis (2002)
Ma Behlke (2006)
Gan To Kagaku Ryoho
Y Matsumura (1987)
S Hu-Lieskovan (2005)
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
R. Kircheis (2001)
Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor.
P. Yazdi (1995)
Nucl Med Biol
N Liu (2007)
This paper is referenced by
Imaging targeted-agent binding in vivo with two probes.
B. Pogue (2010)
A status report on RNAi therapeutics
A. Vaishnaw (2010)
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting
K. Tsekouras (2013)
Cyclodextrin-based host-guest supramolecular nanoparticles for delivery: from design to applications.
Q. Hu (2014)
ReviewA status report on RNAi therapeutics
A. Vaishnaw (2015)
Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia.
Zhiyong Poon (2011)
Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
M. van Elk (2016)
Tumor delivery of macromolecular drugs based on the EPR effect.
V. Torchilin (2011)
A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.
Cheng-qiong Mao (2011)
Knocking down barriers: advances in siRNA delivery
K. Whitehead (2009)
Quantitative in vivo imaging of non-viral-mediated gene expression and RNAi-mediated knockdown.
Garrett R Rettig (2009)
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
Yiming Zhao (2016)
Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes.
Yuvraj Singh (2015)
Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
J. Wang (2018)
Copper- 6 4cals for Oncologic Imaging
J. Holland (2009)
Bioengineering targeted nanodrugs for hematologic malignancies: An innovation in pediatric oncology
V. Krishnan (2015)
Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
A. L. Petersen (2012)
Supramolecular assemblies in functional siRNA delivery: where do we stand?
Hamidreza M. Aliabadi (2012)
The ligand nanoparticle conjugation approach for targeted cancer therapy.
Nour Karra (2012)
Development of nanoscale delivery systems for breast cancer treatment
Y. Zhang (2015)
Activatable cell penetrating peptides and their use in clinical contrast agent and therapeutic development
Todd A. Aguilera (2009)
Delivery of RNA interference therapeutics using polycation-based nanoparticles.
K. Howard (2009)
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
S. Capolla (2015)
Development of nanoparticle platform for therapeutic siRNA and drug delivery to breast cancer
Worapol Ngamcherdtrakul (2015)
Nanotechnologies in cancer treatment and diagnosis.
Stephanie A. Morris (2014)
Perspectives on Nanotechnology
Aleksandar F. Radovic-Moreno (2011)
Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.
G. Liu (2011)
Hierarchical design of a polymeric nanovehicle for efficient tumor regression and imaging.
Jinxia An (2016)
A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density
B. Gray (2013)
Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Xian-Zhu Yang (2011)
Biocompatible surface-enhanced Raman scattering nanotags for in vivo cancer detection.
A. Samanta (2014)
Photoswitchable nanoparticles for in vivo cancer chemotherapy
R. Tong (2013)See more